在克罗恩病中重新评估治疗策略:比较Modulen和budesonide
Chloe Lahoud1, Toni Habib1, Elie Bou Sanayeh1
1Department of Internal Medicine, Staten Island University Hospital, New York, NY 10305, United States.
World journal of gastroenterology
|June 20, 2025
概括
营养疗法 (Modulen) 显示出与布德索尼德治疗克罗恩病的疗效相似. 需要进一步的研究来改善坚持并将营养方法纳入治疗计划.
科学领域:
- 胃肠病学 胃肠病学
- 炎症性肠道疾病研究研究
- 营养科学 营养科学
背景情况:
- 克罗恩氏病的治疗常常依赖于诸如布索尼德 (budesonide) 这样的药物治疗.
- 营养干预被认为具有治疗潜力,但未得到充分利用.
- 粘膜愈合是克罗恩病治疗的关键终点.
研究的目的:
- 为了比较一种特定的营养干预 (Modulen) 与常规药物治疗 (budesonide) 的疗效,用于克罗恩病的粘膜愈合.
- 突出营养方法在管理炎症性肠病中的潜力.
- 探索将营养疗法整合到临床实践中的挑战和机遇.
主要方法:
- 评估Modulen与budesonide之间的比较研究设计.
- 评估粘膜愈合作为主要结果.
- 分析患者的坚持和戒断率.
主要成果:
- 莫杜伦在促进粘膜愈合方面显示出与布德索尼德可比的治疗益处.
- 发现的一个重大挑战是,由于坚持问题,Modulen的退出率很高.
- 这项研究强调了营养干预在实现内镜治疗中的潜力.
结论:
- 营养疗法为克罗恩病的药物治疗提供了一个可行的替代方案或辅助方法.
- 解决坚持挑战对于优化营养干预措施的使用至关重要.
- 结合药理和非药理方法的综合治疗策略对于综合性疾病管理至关重要.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
430
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
430
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240


